Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 2
2011 4
2012 2
2013 5
2014 6
2015 8
2016 17
2017 11
2018 11
2019 15
2020 11
2021 13
2022 13
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Management of relapsed/refractory mantle cell lymphoma.
Alzahrani M, Villa D. Alzahrani M, et al. Among authors: villa d. Leuk Lymphoma. 2024 Apr 18:1-11. doi: 10.1080/10428194.2024.2338851. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38635491 Review.
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment.
Zaikova E, Cheng BYC, Cerda V, Kong E, Lai D, Lum A, Bates C, den Brok W, Kono T, Bourque S, Chan A, Feng X, Fenton D, Gurjal A, Levasseur N, Lohrisch C, Roberts S, Shenkier T, Simmons C, Taylor S, Villa D, Miller R, Aguirre-Hernandez R, Aparicio S, Gelmon K. Zaikova E, et al. Among authors: villa d. NPJ Breast Cancer. 2024 Jan 5;10(1):3. doi: 10.1038/s41523-023-00607-1. NPJ Breast Cancer. 2024. PMID: 38182588 Free PMC article.
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim JL, Gerrie AS, Savage KJ, Villa D, Scott D, Craig JW, Farinha P, Skinnider B, Slack G, Connors JM, Sehn LH, Venner C, Freeman CL. Kim JL, et al. Among authors: villa d. Leuk Lymphoma. 2024 Mar;65(3):346-352. doi: 10.1080/10428194.2023.2290466. Epub 2023 Dec 29. Leuk Lymphoma. 2024. PMID: 38156444
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
Ramsower CA, Rosenthal A, Robetorye RS, Mwangi R, Maurer M, Villa D, McDonnell T, Feldman A, Cohen JB, Habermann T, Campo E, Clot G, Bühler MM, Kulis M, Martin-Subero JI, Giné E, Cook JR, Hill B, Raess PW, Beiske KH, Reichart A, Hartmann S, Holte H, Scott D, Rimsza L. Ramsower CA, et al. Among authors: villa d. Br J Haematol. 2024 Jan;204(1):160-170. doi: 10.1111/bjh.19153. Epub 2023 Oct 25. Br J Haematol. 2024. PMID: 37881141
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, Cohen JB, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, Fenske T, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Gerson JN, et al. Among authors: villa d. Blood Adv. 2023 Dec 26;7(24):7393-7401. doi: 10.1182/bloodadvances.2023010757. Blood Adv. 2023. PMID: 37874912 Free PMC article.
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC, Cheah CY; International CNS Prophylaxis Study Group. Lewis KL, et al. Among authors: villa d. J Clin Oncol. 2023 Dec 10;41(35):5376-5387. doi: 10.1200/JCO.23.00365. Epub 2023 Oct 5. J Clin Oncol. 2023. PMID: 37797284
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, Wong JCH, Cruz M, Roth A, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Freeman CL, Villa D, Rodrigo JA, Song K, Crump M, Shepherd L, Hay AE, Kuruvilla J, Savage KJ, Kridel R, Karsan A, Marra MA, Sehn LH, Steidl C, Morin RD, Scott DW. Hilton LK, et al. Among authors: villa d. J Clin Oncol. 2023 Sep 1;41(25):4164-4177. doi: 10.1200/JCO.23.00570. Epub 2023 Jun 15. J Clin Oncol. 2023. PMID: 37319384
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, El-Galaly TC, Kugathasan L, Scott DW, Gerrie AS, Lewis D. Villa D, et al. Blood Adv. 2023 Aug 22;7(16):4576-4585. doi: 10.1182/bloodadvances.2023009804. Blood Adv. 2023. PMID: 37307169 Free PMC article.
114 results